<DOC>
	<DOCNO>NCT01095822</DOCNO>
	<brief_summary>People hypertension diabetes high chance develop heart arterial problem could reduce anti-coagulant therapy . Valsartan ( Diovan ) , FDA approve angiotensin-II receptor antagonist ( blocker ) clinically indicate treatment essential hypertension know inhibit platelet activity vitro ex vivo set . Aliskiren ( Tekturna ) recently FDA-approved potent direct renin inhibitor also effective anti-hypertensive agent patient mild-to-moderate hypertension , vitro , modulate antithrombin III plasma . Therefore , addition clinically approve anti-hypertensive medication , combine two agent potentially target primary hemostasis ( platelet ) anticoagulant ( antithrombin-III cornerstone substrate heparin ) property exert anti-thrombotic efficacy simultaneously . This combination strategy may improve hypertension management , also improve vascular outcome high-risk diabetic population via favorable effect anti-thrombotic activity . Importantly , significant additional safety concern use combination aliskiren valsartan . The investigator hypothesis valsartan 160 mg/daily combination aliskiren 150-300 mg/daily 4 week favorably affect blood level platelet/coagulation/fibrinolytic biomarkers ( ie , diminish platelet activity , enhance antithrombin III potency ) compare monotherapy aliskiren 150mg/daily hypertensive patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Effects Valsartan Aliskiren Hemostatic Indices Hypertensive Diabetics</brief_title>
	<detailed_description>Objectives : There 2 objective index study . • The primary objective determine therapy valsartan ( 160mg/daily ) combination aliskiren ( 150-300mg/daily ) four week affect platelet/coagulation/fibrinolytic biomarkers recently diagnose hypertensive patient type 2 diabetes mellitus . However , exploratory study , current knowledge base vitro ex vivo evidence valsartan , vitro aliskiren data . There data antithrombotic biomarkers currently available combination therapy . The secondary objective : • To define whether combination therapy superior monotherapy aliskiren regard improvement hemostatic biomarkers ( platelet aggregation , expression GP IIb/IIIa , plasma level antithrombin-III ) . Study Design : This randomize 1:1 , two arm , single-blind , single-site , parallel group , post-marketing comparison study effect antithrombotic biomarkers aliskiren 150-300mg/day alone v combine treatment aliskiren 150-300mg/day plus valsartan 160mg/day four week primary treatment period . An optional four week extension phase may offer pending assessment antithrombotic biomarker assay week four . Population : Two group ( 25 patient ) , total 50 , recently diagnose hypertensive patient previously diagnose mild moderate type 2 diabetes constitute propose study population . The diagnosis diabetes make base American Diabetes Association criterion , random plasma glucose &gt; 200 mg/dL without symptom hyperglycemia ( polydipsia , polyuria , polyphagia ) weight loss , fast plasma glucose &gt; 126 mg/dL , determine least twice . Patients qualify insulin-free , treated oral antiglycemic agent , ( metformin ) and/or manage diet alone less 30 day adequate glucose control time Screening Visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . The diagnosis Type 2 Diabetes Mellitus determine follow Criteria , characterize recurrent persistent hyperglycemia , diagnose demonstrate one follow . Fasting plasma glucose level 126 mg/dL less 250 mg/dL one determination . Plasma glucose 200 mg/dL two hour 75 g oral glucose load glucose tolerance test . Symptoms hyperglycemia casual plasma glucose 200 mg/dL . Glycated hemoglobin ( hemoglobin A1C ) 6.5 8.5 % . ( This criterion recommend American Diabetes Association 2010 ) . 2 . Adults 21 65 year old 3 . Have diagnose Type 2 DM accord criterion list , treat metformin 12 g/daily diabetic medication , and/or approve ADA diet less 30 day . 4 . Documented evidence Stage 1 Stage 2 essential hypertension note : However , actual treatment threshold leave discretion study investigator . Stage 1 : systolic 140159 mmHg diastolic 9099 mmHg Stage 2 : systolic &gt; 160 mmHg diastolic &gt; 100 mmHg However , accumulate evidence patient consistent blood pressure 130/80 mmHg along Type 1 Type 2 diabetes , kidney disease increase risk progressive morbidity mortality require low threshold treatment . 5 . Aspirin 81 mg/daily 6 . Signed informed consent 7 . Must maintain diet/exercise regimen 1 . Thrombolytic therapy , GP IIb/IIIa inhibitor , thienopyridines , antifibrinolytics , COX inhibitor , prostacyclin analogue , vitamin K antagonist within 30 day enrollment 2 . Platelet count &lt; 100,000/microL 3 . History bleed disorder 4 . Hct &lt; 30 % , serum creatinine ≥3 mg/dL , liver impairment define ALT/AST &gt; 3 time upper limit normal . 5 . Glomerular filtration rate &lt; 60ml/min/1.73m2 6 . Patients currently treat antiplatelet agent aspirin 81 mg/day 7 . Admission acute vascular syndrome ( unstable angina , MI , stroke ) , revascularization procedure stent placement , major coronary/cerebrovascular event within 30 day . 8 . Active participation investigational drug device trial within last 30 day . 9 . Allergy intolerance study medication . 10 . Congestive Heart Failure ( NYHA IIV ) 11 . Malignancies except treated nonmelanoma superficial skin cancer 12 . Acute infection 13 . Type I diabetes , Cushings syndrome , pancreatic deficiency due malignancy systemic disease 14 . Insulin therapy , sulfonylurea , thiazolidinediones , meglitinides , Dphenylalanine derivatives , amylin synthetic derivative , incretin mimetics . 15 . Pregnancy , confirm serum rosette inhibition assay early pregnancy factor detectable . For woman childbearing potential ( WOCP ) , continuous abstinence , fertility awareness , hormonal contraceptive , and/or mechanical method apply prevent pregnancy entire study duration . Should subject become pregnant study , antihypertensive treatment either study medication discontinue immediately treat physician/investigator per FDA warning regard potential fetal/neonatal morbidity mortality . 16 . Age 65 year 17 . History cigarette smoking within past 10 year</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Platelets</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Aliskiren</keyword>
	<keyword>Valsartan</keyword>
</DOC>